Pushpa Naga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pushpa Naga has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Lavanya Gurram
Department of Radiation Oncology and Medical Physics, Tata Memorial Centre, Homi-Bhabha National Institute, Mumbai, India
4 shared publicationsR. Engineer
Tata Mem Hosp, Radiat Oncol, Bombay, Maharashtra, India
4 shared publicationsS. Gupta
Tata Mem Hosp, Med Oncol, Mumbai, Maharashtra, India
4 shared publicationsSupriya Chopra
Department of Radiation Oncology and Medical Physics, Tata Memorial Centre, Homi-Bhabha National Institute, Mumbai, India
4 shared publicationsJ. Ghosh
3 shared publicationsJ. Swamidas
3 shared publications
Latest Publications
- 1 December 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 102 (5) , 1448-1456
A Prospective Comparison of Computed Tomography with Transrectal Ultrasonography Assistance and Magnetic Resonance Imaging–Based Target-Volume Definition During Image Guided Adaptive Brachytherapy for Cervical Cancers
- 1 December 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 102 (5) , 1448-1456
A Prospective Comparison of Computed Tomography with Transrectal Ultrasonography Assistance and Magnetic Resonance Imaging–Based Target-Volume Definition During Image Guided Adaptive Brachytherapy for Cervical Cancers
- 3 October 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1092) , 20180005
Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin
Objective: To report acute hematological toxicity (HT) in patients receiving post-operative bowel sparing intensity-modulated radiotherapy (IMRT) and cisplatin and its dosimetric predictors. Methods: Clinical database of Phase III trial (NCT01279135), that randomized patients to post-operative conformal or intensity modulated radiation therapy, was searched to select patient strata that received bowel sparing IMRT (50 Gy/25#/5 wks) and concurrent cisplatin (40 mg m– 2). Pelvic bone marrow (BM) was retrospectively delineated in two sets: whole bone (WB), and freehand (FH) inner cavity of bone. Dose volume histograms (DVH) of BM were obtained. Receiver operating characteristic (ROC) curve identified DVH thresholds that predicted for Grade≥ II HT with highest specificity. Univariate and multivariate analysis was performed. Results: Overall 75 patients received concurrent cisplatin. Grades I–V HT was observed in 38.7%, 42.7%, 14.7%, 0%, and 0% patients, respectively. Grade ≥ II leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 26%, 40%, 26.5%, and 1.4% respectively. None of the HT resulted in treatment break. On univariate analysis, whole pelvis+ lumbar FH V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, and lower pelvis WB and FH V40 >20% correlated for Grade ≥ II leucopenia and neutropenia. None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis. Conclusion: The IMRT arm of NCT01279135 (PARCER study) that employed strict bowel constraints had unintentional but desirable BM sparing. None of the BM subvolume DVH parameters could be validated on multivariate analysis. Advances in knowledge: The prospective study reports feasibility of bone marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cervical cancer. The present study reports low incidence of hematological and gastrointestinal toxicity during post-operative chemoradiation with IMRT. As both whole bone and freehand pelvis BM contours predicted for HT, hence an easier method of whole bone contouring should continue to be used till further validation of more specific BM subvolumes becomes available. The study results highlight the need for further research into dose volume constraints during post-operative IMRT.
- 3 October 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1092) , 20180005
Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin
Objective: To report acute hematological toxicity (HT) in patients receiving post-operative bowel sparing intensity-modulated radiotherapy (IMRT) and cisplatin and its dosimetric predictors. Methods: Clinical database of Phase III trial (NCT01279135), that randomized patients to post-operative conformal or intensity modulated radiation therapy, was searched to select patient strata that received bowel sparing IMRT (50 Gy/25#/5 wks) and concurrent cisplatin (40 mg m– 2). Pelvic bone marrow (BM) was retrospectively delineated in two sets: whole bone (WB), and freehand (FH) inner cavity of bone. Dose volume histograms (DVH) of BM were obtained. Receiver operating characteristic (ROC) curve identified DVH thresholds that predicted for Grade≥ II HT with highest specificity. Univariate and multivariate analysis was performed. Results: Overall 75 patients received concurrent cisplatin. Grades I–V HT was observed in 38.7%, 42.7%, 14.7%, 0%, and 0% patients, respectively. Grade ≥ II leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 26%, 40%, 26.5%, and 1.4% respectively. None of the HT resulted in treatment break. On univariate analysis, whole pelvis+ lumbar FH V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, and lower pelvis WB and FH V40 >20% correlated for Grade ≥ II leucopenia and neutropenia. None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis. Conclusion: The IMRT arm of NCT01279135 (PARCER study) that employed strict bowel constraints had unintentional but desirable BM sparing. None of the BM subvolume DVH parameters could be validated on multivariate analysis. Advances in knowledge: The prospective study reports feasibility of bone marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cervical cancer. The present study reports low incidence of hematological and gastrointestinal toxicity during post-operative chemoradiation with IMRT. As both whole bone and freehand pelvis BM contours predicted for HT, hence an easier method of whole bone contouring should continue to be used till further validation of more specific BM subvolumes becomes available. The study results highlight the need for further research into dose volume constraints during post-operative IMRT.
- 1 September 2018
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 30 (5) , 323-329
The management of locally advanced cervical cancer
Purpose of review: Cervical cancer is still a major cause of morbidity and mortality among women worldwide. Surgery and chemoradiation are widely utilized treatments for cervical cancer. Despite the available standard treatment of choice, outcome is suboptimal among patients with LACC. It is vital to integrate the evidence generated from high-quality research work for effective management of these cases. This review intends to critically evaluate the latest evidence supporting the available treatment modalities and to provide a comprehensive overview of recent advances and ongoing research in the management of LACC. Recent findings: Research advances in imaging and radiotherapy technologies, incorporating imaging into brachytherapy planning, use of newer targeted agents, chemotherapy intensification and immunotherapy are some of the new therapeutic options that have been in the forefront of research to improve the outcome of patients with LACC. Summary: Advanced imaging modalities are increasingly being utilized to tailor treatments. Neoadjuvant chemotherapy followed by surgery does not improve outcomes in FIGO Stage IB2–IIB. Although cisplatin-based concurrent chemoradiation is the standard of care, more aggressive systemic therapies (neoadjuvant or adjuvant chemotherapy and chemoradiation) and use of newer agents, still remains investigational.
- 1 September 2018
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 30 (5) , 323-329
The management of locally advanced cervical cancer
Purpose of review: Cervical cancer is still a major cause of morbidity and mortality among women worldwide. Surgery and chemoradiation are widely utilized treatments for cervical cancer. Despite the available standard treatment of choice, outcome is suboptimal among patients with LACC. It is vital to integrate the evidence generated from high-quality research work for effective management of these cases. This review intends to critically evaluate the latest evidence supporting the available treatment modalities and to provide a comprehensive overview of recent advances and ongoing research in the management of LACC. Recent findings: Research advances in imaging and radiotherapy technologies, incorporating imaging into brachytherapy planning, use of newer targeted agents, chemotherapy intensification and immunotherapy are some of the new therapeutic options that have been in the forefront of research to improve the outcome of patients with LACC. Summary: Advanced imaging modalities are increasingly being utilized to tailor treatments. Neoadjuvant chemotherapy followed by surgery does not improve outcomes in FIGO Stage IB2–IIB. Although cisplatin-based concurrent chemoradiation is the standard of care, more aggressive systemic therapies (neoadjuvant or adjuvant chemotherapy and chemoradiation) and use of newer agents, still remains investigational.
- 1 July 2018
- Published by Elsevier in Brachytherapy
- Vol. 17 (4) , S39-S40
Vienna Ii Ring Applicator for Distal Parametrial Disease in Cervical Cancer Image Guided Brachytherapy: Clinical Feasibility and Outcome in a Two-Institutional Setting
- 1 July 2018
- Published by Elsevier in Brachytherapy
- Vol. 17 (4) , S39-S40
Vienna Ii Ring Applicator for Distal Parametrial Disease in Cervical Cancer Image Guided Brachytherapy: Clinical Feasibility and Outcome in a Two-Institutional Setting
- Open Access
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S199-S200
OC-0390: Clinical outcome with dose escalation using IMRT in Cervical Cancer: A phase II randomized trial
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S199-S200
Open AccessOC-0390: Clinical outcome with dose escalation using IMRT in Cervical Cancer: A phase II randomized trial
- 1 February 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (2) , 299-304
Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study
- 1 February 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (2) , 299-304
Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E306-E307
Prospective Validation of Bone Marrow Constraints for Hematological Toxicity in Patients Undergoing Chemoradiation for Cervical Cancer
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E306-E307
Prospective Validation of Bone Marrow Constraints for Hematological Toxicity in Patients Undergoing Chemoradiation for Cervical Cancer
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S226
Hematological Toxicity during Pelvic IMRT Versus 3DCRT: Secondary Analysis from Phase 3 RCT
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S226
Hematological Toxicity during Pelvic IMRT Versus 3DCRT: Secondary Analysis from Phase 3 RCT
- 1 September 2017
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 48 (3) , 307-315
Accelerated Radiation Therapy Using Weekend Boost with Concurrent Cisplatin in Head and Neck Squamous Cell Cancers: An Indian Institutional Experience
- 1 September 2017
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 48 (3) , 307-315
Accelerated Radiation Therapy Using Weekend Boost with Concurrent Cisplatin in Head and Neck Squamous Cell Cancers: An Indian Institutional Experience
- 1 September 2017
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 48 (3) , 288-293
Quantification of Dose-Volume and Dose-Length Parameters for Cervical Esophageal Stricture in Head and Neck Irradiation with the 3DCRT and IMRT Technique
- 1 September 2017
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 48 (3) , 288-293
Quantification of Dose-Volume and Dose-Length Parameters for Cervical Esophageal Stricture in Head and Neck Irradiation with the 3DCRT and IMRT Technique